Emergency Medication Needs: Hurricane Katrina
Dear AIDS Drug Assistance Program Directors:
In response to the emergency medication needs of HIV-positive individuals displaced by Hurricane Katrina, Gilead Sciences will donate, free of charge, replacement medications for Truvada® (emtricitabine and tenofovir disoproxil fumarate), Viread® (tenofovir disoproxil fumarate), Emtriva® (emtricitabine) and Hepsera® (adefovir dipivoxil) provided by the state AIDS Drug Assistance Programs in Texas, Arkansas, Georgia, Tennessee, Florida, Louisiana, Mississippi and Alabama to out-of-state, displaced individuals.
In order to receive donated product, please fax a letter of request on state letterhead to Kristie Banks at Gilead Sciences at 1-800-693-9009. To reach Kristie directly by phone, please call 650-522-5279. The letter should clearly state that you are requesting donated replacement medications for Gilead products dispensed by your program to out-of-state individuals displaced by Hurricane Katrina. Please include full contact information for your program and your Federal Tax ID Number.
Please submit an invoice labeled "request for donated medications -- Hurricane Katrina" for the number of bottles of Truvada, Viread, Emtriva or Hepsera dispensed by your program for which you are seeking replacement. Please include full shipping and contact information on the invoice.
Gilead will offer replacement medications through October 31, 2005. At that time we will evaluate the need for continued support and the availability of alternative resources. All invoices for medications dispensed September 1, 2005 - October 31, 2005 must be submitted to Gilead by November 30, 2005.
For patients not accessing emergency medication coverage through one of the state ADAPs listed above, Gilead will offer expedited enrollment in our "Advancing Access" Patient Assistance Program via telephone, waiving the standard documentation requirements for individuals displaced by Hurricane Katrina who are in need of Truvada, Viread, Emtriva, or Hepsera. Patients will be provided with one original 30-day prescription and one 30-day refill. After the initial 60-day period, patients should formally enroll in the Advancing Access Program. We will continue to evaluate patient needs at that time. The telephone number for the Advancing Access program is 1-800-226-2056.
Please do not hesitate to contact me on my mobile phone at 650-787-2162 over the weekend if you have any questions about the assistance Gilead is offering.
Coy A. Stout, II, M.S.W.
Senior Director, National Accounts